Development of new medical treatment for epithelial ovarian cancer recurrence

Epithelial ovarian cancer (EOC) is the scariest gynaecological cancer. Many advances have been done with evolving knowledge, leading to the introduction of new drugs, most in maintenance setting. The antiangiogenic Bevacizumab and the three approved PARP-inhibitors—olaparib, niraparib and rucaparib—...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Gland Surg
Главные авторы: Mancari, Rosanna, Cutillo, Giuseppe, Bruno, Valentina, Vincenzoni, Cristina, Mancini, Emanuela, Baiocco, Ermelinda, Bruni, Simone, Vocaturo, Giuseppe, Chiofalo, Benito, Vizza, Enrico
Формат: Artigo
Язык:Inglês
Опубликовано: AME Publishing Company 2020
Предметы:
Review Article on Ovarian Cancer Recurrence
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7475356/
https://ncbi.nlm.nih.gov/pubmed/32953630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/gs-20-413
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы